Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28534850 | 0.85 | AKR1C3 (0.60) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6152954 | 0.84 | CES2 (0.65) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL28428441 | 0.84 | SMN1; SMN2 (0.53) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25107699 | 0.84 | KMT2A (0.50) | CES2CES1NPC1RAB9AMEN1 | |
| SCHEMBL9006943 | 0.84 | CES2 (0.56) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL28710457 | 0.83 | CES2 (0.62) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL1383788 | 0.83 | PARP1 (0.69) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL31135462 | 0.82 | CES2 (0.79) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL4737739 | 0.82 | CES2 (0.79) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL25108845 | 0.82 | EPHX2 (0.47) | CES2CES1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2024245143-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | 赛诺哈勃药业（成都）有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| EP-3852792-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852790-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113164571-A | Inhibition of ubiquitin-specific peptidase 9X | 福马治疗股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021055668-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020191022-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020061261-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061252-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| CN-109153840-A | Polymer-containing composition and antifouling coating composition | 三菱化学株式会社 | 2019-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, RBX1, USP19 | CES2 4227/4885CES1 2065/4885PARP1 561/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | CES2 3558/4885CES1 795/4885PARP1 2498/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | CES2 2870/4885CES1 671/4885PARP1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.